Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study.
Journal
Schizophrenia (Heidelberg, Germany)
ISSN: 2754-6993
Titre abrégé: Schizophrenia (Heidelb)
Pays: Germany
ID NLM: 9918367987006676
Informations de publication
Date de publication:
12 Jul 2022
12 Jul 2022
Historique:
received:
04
11
2021
accepted:
23
05
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
Impaired cognition is associated with lower quality of life and poor outcomes in schizophrenia. Brain glutamate may contribute to both clinical outcomes and cognition, but these relationships are not well-understood. We studied a multicentre cohort of 85 participants with non-affective psychosis using proton magnetic resonance spectroscopy. Glutamate neurometabolites were measured in the anterior cingulate cortex (ACC). Cognition was assessed using the Brief Assessment for Cognition in Schizophrenia (BACS). Patients were categorised as antipsychotic responders or non-responders based on treatment history and current symptom severity. Inverted U-shaped associations between glutamate or Glx (glutamate + glutamine) with BACS subscale and total scores were examined with regression analyses. We then tested for an interaction effect of the antipsychotic response group on the relationship between glutamate and cognition. ACC glutamate and Glx had a positive linear association with verbal memory after adjusting for age, sex and chlorpromazine equivalent dose (glutamate, β = 3.73, 95% CI = 1.26-6.20, P = 0.004; Glx, β = 3.38, 95% CI = 0.84-5.91, P = 0.01). This association did not differ between good and poor antipsychotic response groups. ACC glutamate was also positively associated with total BACS score (β = 3.12, 95% CI = 0.01-6.23, P = 0.046), but this was not significant after controlling for antipsychotic dose. Lower glutamatergic metabolites in the ACC were associated with worse verbal memory, and this relationship was independent of antipsychotic response. Further research on relationships between glutamate and cognition in antipsychotic responsive and non-responsive illness could aid the stratification of patient groups for targeted treatment interventions.
Identifiants
pubmed: 35853881
doi: 10.1038/s41537-022-00265-5
pii: 10.1038/s41537-022-00265-5
pmc: PMC9279335
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60Subventions
Organisme : Medical Research Council
ID : MC_PC_19041
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N027078/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U120097115
Pays : United Kingdom
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/L011794/1
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700995
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V013734/1
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Front Psychiatry. 2013 Nov 26;4:151
pubmed: 24324444
BMJ Open. 2021 Nov 25;11(11):e054160
pubmed: 34824121
Biol Psychiatry. 2011 Jan 1;69(1):19-27
pubmed: 20970118
Neuropsychopharmacology. 2020 Mar;45(4):632-640
pubmed: 31842203
Mol Psychiatry. 2015 Oct;20(10):1151-60
pubmed: 26077694
Mol Psychiatry. 2018 Nov;23(11):2145-2155
pubmed: 29880882
Curr Pharm Des. 2010;16(5):488-501
pubmed: 19909227
Int J Neuropsychopharmacol. 2005 Sep;8(3):457-72
pubmed: 15784157
J Clin Psychopharmacol. 2004 Apr;24(2):192-208
pubmed: 15206667
Am J Psychiatry. 1999 Sep;156(9):1358-66
pubmed: 10484945
Neuropsychology. 1998 Jul;12(3):426-45
pubmed: 9673998
Arch Gen Psychiatry. 2007 Oct;64(10):1115-22
pubmed: 17909123
BMC Psychiatry. 2017 Jan 13;17(1):12
pubmed: 28086761
Psychol Med. 2019 Sep;49(12):2100-2110
pubmed: 30348234
Eur J Clin Pharmacol. 2014 Feb;70(2):127-34
pubmed: 24145817
Schizophr Bull. 2012 Sep;38(5):942-9
pubmed: 22899397
Biol Psychiatry. 2004 May 15;55(10):1013-22
pubmed: 15121486
Psychiatry Res. 2015 Aug 30;233(2):180-5
pubmed: 26163385
Schizophr Res. 2004 Jun 1;68(2-3):283-97
pubmed: 15099610
Neuropsychopharmacology. 2014 Nov;39(12):2742-9
pubmed: 24487737
Psychol Med. 2022 Jan;52(1):1-13
pubmed: 36415088
Neuropsychiatr Dis Treat. 2007 Feb;3(1):87-101
pubmed: 19300540
Neuropsychopharmacology. 1997 Sep;17(3):141-50
pubmed: 9272481
JAMA Psychiatry. 2014 Jun;71(6):637-46
pubmed: 24696094
Psychopharmacology (Berl). 2007 Sep;193(4):521-37
pubmed: 17497138
Schizophr Bull. 2021 Apr 29;47(3):662-671
pubmed: 33398325
Neuropsychopharmacology. 2012 Jan;37(1):4-15
pubmed: 21956446
Neuroimage. 2010 Feb 1;49(3):2783-90
pubmed: 19850131
JAMA Psychiatry. 2021 Jun 1;78(6):667-681
pubmed: 33881460
Schizophr Res. 2008 Feb;99(1-3):155-63
pubmed: 17616347
Schizophr Res. 2009 Sep;113(2-3):189-99
pubmed: 19628375
Neuropsychology. 2009 May;23(3):315-36
pubmed: 19413446
JAMA Psychiatry. 2018 Jan 1;75(1):11-19
pubmed: 29167877
Magn Reson Med. 2016 Jan;75(1):15-8
pubmed: 25753153
Schizophr Bull. 2013 Jan;39(1):120-9
pubmed: 21746807
Am J Psychiatry. 2008 Feb;165(2):203-13
pubmed: 18172019
Schizophr Res. 2014 Sep;158(1-3):156-62
pubmed: 25086658
JAMA Psychiatry. 2019 Mar 1;76(3):314-323
pubmed: 30624573
Neuroimage Clin. 2014 Apr 02;4:576-84
pubmed: 24749064
Schizophr Res. 2022 Nov;249:74-84
pubmed: 32107102
JAMA Psychiatry. 2021 Jun 16;:
pubmed: 34132736
Schizophr Res. 2008 Dec;106(2-3):156-63
pubmed: 18799290
Psychopharmacology (Berl). 2008 Feb;196(3):451-60
pubmed: 17952411
Neuropsychopharmacology. 1995 Aug;13(1):9-19
pubmed: 8526975
Schizophr Bull. 2021 Mar 16;47(2):505-516
pubmed: 32910150
Schizophr Bull. 2017 May 1;43(3):611-619
pubmed: 27550776
J Psychiatr Res. 2007 Oct;41(8):625-34
pubmed: 16949099
Am J Psychiatry. 2001 Sep;158(9):1367-77
pubmed: 11532718
Transl Psychiatry. 2016 Nov 29;6(11):e967
pubmed: 27898072
Magn Reson Imaging. 2008 Jun;26(5):667-75
pubmed: 17692491
JAMA Psychiatry. 2016 Feb;73(2):166-74
pubmed: 26720179
World Psychiatry. 2020 Feb;19(1):15-33
pubmed: 31922684
NPJ Schizophr. 2019 Aug 1;5(1):12
pubmed: 31371817
Trends Cogn Sci. 2000 Jun;4(6):215-222
pubmed: 10827444
Schizophr Bull. 2013 Sep;39(5):1096-104
pubmed: 23081992
Front Psychiatry. 2018 Feb 06;9:22
pubmed: 29467681
Curr Pharm Des. 2010;16(5):522-37
pubmed: 19909229
Neuropsychopharmacology. 2012 Oct;37(11):2515-21
pubmed: 22763619
Schizophr Res. 2008 Jul;102(1-3):108-15
pubmed: 18495435
Biol Psychiatry. 2019 Apr 1;85(7):596-605
pubmed: 30389132
Front Psychiatry. 2014 Jan 08;4:182
pubmed: 24409157
Mol Psychiatry. 2021 Jul;26(7):3502-3511
pubmed: 33077854
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
pubmed: 8122957
JAMA Netw Open. 2020 May 1;3(5):e204693
pubmed: 32437573
Isr J Psychiatry Relat Sci. 2010;47(1):4-16
pubmed: 20686195
Schizophr Bull. 2016 May;42(3):744-52
pubmed: 26683625
Arch Gen Psychiatry. 2012 Jun;69(6):562-71
pubmed: 22664547
Biol Psychiatry. 2010 Oct 1;68(7):625-33
pubmed: 20570244
Psychopharmacology (Berl). 2014 Feb;231(3):511-9
pubmed: 24051602
Arch Gen Psychiatry. 2012 May;69(5):449-59
pubmed: 22213769
J Pharmacol Exp Ther. 1995 Sep;274(3):1209-15
pubmed: 7562490
Acta Psychiatr Scand. 2014 Jul;130(1):1-15
pubmed: 24611632
Neuropsychopharmacology. 1997 Aug;17(2):92-9
pubmed: 9252984
Neuropharmacology. 2020 Aug 1;172:107704
pubmed: 31299229
Int J Neuropsychopharmacol. 2015 Jan 20;18(6):
pubmed: 25603859
BMJ. 1996 Feb 10;312(7027):345-9
pubmed: 8611831
Biol Psychiatry. 2021 Feb 1;89(3):278-287
pubmed: 32928500